Faculty of Health Sciences, Department of Nursing Science, Physiotherapy and Medicine, University of Almeria, Ctra. Sacramento s/n, 04120 Almeria, Spain.
Faculty of Health Sciences, Pre-Department of Nursing, Jaume I University, Av. Sos Baynat, 12071 Castello de la Plana, Spain.
Benef Microbes. 2021 Feb 24;12(1):5-15. doi: 10.3920/BM2020.0111. Epub 2021 Jan 17.
Obesity and overweight are two of the most health challenges with an increasing prevalence in recent years, in which several complications have been identified to have a high impact in patients' health conditions. In this vein, an increasing interest in the gut microbiota has emerged as a target for therapeutic strategies in obesity and overweight due to its direct relation with the aforementioned health conditions and complications. Thus, the aim of this study was to evaluate the efficacy of probiotics as a therapeutic strategy in the management of obesity and overweight. A systematic review of randomised controlled trials was carried out in 6 databases until May 2019 to assess the use of probiotics in obesity and overweight patients. The Jadad Scale was used to assess the quality of the clinical trials. Twenty-three clinical trials published between 2000 and 2019 met the inclusion criteria. The role of probiotics in reducing body mass index and weight as well as changing the visceral abdominal fat area, waist and hip circumference were shown in 14 of 23 trials (60.87%); 14 trials (60.87%) showed changes on patients' fatty acids and biomarkers; and 4 trials (17.39%) studied the role of the gut microbiota in obese and overweight patients. Some probiotics strains are shown to be effective in reducing body mass index and hip circumference. This review provides evidence of successful results in weight loss using probiotic groups.
肥胖和超重是近年来发病率不断上升的两大健康挑战，其中已确定多种并发症对患者的健康状况有重大影响。因此，人们对肠道微生物群越来越感兴趣，将其作为肥胖和超重治疗策略的一个靶点，因为它与上述健康状况和并发症直接相关。因此，本研究旨在评估益生菌作为肥胖和超重管理治疗策略的疗效。我们在 6 个数据库中进行了一项随机对照试验的系统评价，以评估益生菌在肥胖和超重患者中的应用。使用 Jadad 量表评估临床试验的质量。2000 年至 2019 年间发表的 23 项临床试验符合纳入标准。23 项试验中的 14 项（60.87%）表明益生菌在降低体重指数和体重以及改变内脏腹部脂肪面积、腰围和臀围方面有作用；14 项试验（60.87%）显示出患者脂肪酸和生物标志物的变化；4 项试验（17.39%）研究了肠道微生物群在肥胖和超重患者中的作用。一些益生菌菌株被证明在降低体重指数和臀围方面有效。本综述提供了使用益生菌组成功减肥的证据。
